27 January 2016

From the Program Leader

The Pediatric Praziquantel program has progressed well in 2015, thanks to the great commitment of the consortium partners, the important contribution from the Japanese Global Health Innovative Technology (GHIT) Fund and the Bill and Melinda Gates Foundation, and the valuable input from the World...

We are very excited about what 2016 holds in store for the Consortium, but before we turn that corner we wanted to take the opportunity to share our most important achievements for 2015:

  • Two new child-friendly oral dispersible tablet formulations (L-PZQ ODT and racemate PZQ ODT) showed acceptable palatability when administered to Tanzanian children (swill and spit taste study);
  • The Phase I trials performed in South Africa in healthy adult volunteers to test the bioavailability and tolerability of the new formulations have successfully been completed in the third quarter of 2015;
  • The team is getting ready to start a Phase II trial in Ivory Coast, to determine the efficacy and safety of different doses of ODTs in schistosome-infected children below 6 years of age. The Phase II clinical trial also aims to identify the optimal ODT dose for the subsequent Phase III pediatric trial.

By working together on the developing of a new pediatric praziquantel formulation, the Consortium aims to contribute to the elimination of schistosomiasis. However, the disease can only be successfully eliminated if, amongst other aspects including treatments, vector control becomes part of the global strategy to combat schistosomiasis. Therefore, this edition of the newsletter features, amongst others, an interesting story on a prawn solution to curb the spread of schistosomiasis in West Africa.

We wish you and all the children of the world all the best for 2016!

 

Best wishes,

Dr. Elly Kourany-Lefoll

Consortium Program Leader